Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer

Clinical Breast Cancer

Volumn 14, Issue 3, 2014, Pages 191-197

  Yamauchi, Hideko ^a   Nakagawa, Chizuko ^a   Takei, Hiroyuki ^b   Chao, Calvin ^c   Yoshizawa, Carl ^c   Yagata, Hiroshi ^a   Yoshida, Atsushi ^a   Hayashi, Naoki ^a   Hell, Susanne ^d   Nakamura, Seigo ^a,e  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c Genomic Health Inc   (United States)

^d Medical Affairs Consulting   (Germany)

^e SHOWA UNIVERSITY   (Japan)

Author keywords

Adjuvant; Chemotherapy; Early breast cancer; Multi gene assay; Recurrence Score

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN;

21 GENE ASSAY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CLINICAL STUDY; DOCTOR PATIENT RELATION; EARLY BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; JAPANESE (PEOPLE); KNOWLEDGE; LYMPH NODE NEGATIVE BREAST CANCER; LYMPH NODE POSITIVE BREAST CANCER; MAJOR CLINICAL STUDY; MICROMETASTASIS; MULTICENTER STUDY; PROSPECTIVE STUDY; RECURRENCE SCORE; SCORING SYSTEM; ADJUVANT CHEMOTHERAPY; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CLINICAL TRIAL; DECISION MAKING; DECISION SUPPORT SYSTEM; GENE EXPRESSION PROFILING; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; DECISION SUPPORT TECHNIQUES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTORS, ESTROGEN;

EID: 84899931582     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.10.017     Document Type: Article

References (28)

1. A. Kono, and J. Misumi The time trend of breast cancer mortality in Japan Arch Gynecol Obstet 272 2005 187 190
2. M. Toi, H. Iwata, and T. Yamanaka et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population Cancer 116 2010 3112 3118
3. The Japanese Breast Cancer Society. Available at: http://www.jbcs.gr.jp. Accessed: September 25, 2013.
4. S. Paik, G. Tang, and S. Shak et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 2006 3726 3734
5. J. Esteban, J. Baker, and M. Cronin et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue Prog Proc Am Soc Clin Oncol 22 2003 850 (abstract 3416)
6. M.A. Cobleigh, B. Tabesh, and P. Bitterman et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes Clin Cancer Res 11 2005 8623 8631
7. S. Paik, S. Shak, and G. Tang et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - NSABP studies B-20 and B-14 Breast Cancer Res Treat 82 2003 abstract 16
8. M. Cronin, M. Pho, and D. Dutta et al. Measurement of gene expression in archival paraffin-embedded tissues Am J Pathol 164 2004 35 42
9. M. Cronin, C. Sangli, and M.L. Liu et al. Analytical validation of the Oncotype DX Genomic Diagnostic Test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer Clin Chem 53 2007 1084 1091
10. S. Paik, S. Shak, and G. Tang et al. A multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer N Engl J Med 351 2004 2817 2826
11. M. Dowsett, J. Cuzick, and C. Wale et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study J Clin Oncol 28 2010 1829 1834
12. K. Albain, W.E. Barlow, and S. Shak et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 2010 55 65
13. L. Harris, H. Fritsche, and R. Mennel et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 2007 5287 5312
14. National Comprehensive Cancer Network. Practice Guidelines in Oncology. Breast Cancer (version v3.2013). Available at: http://www.NCCN.org. Accessed September 25, 2013.
15. E. Senkus, S. Kyriakides, and F. Penault-Llorca et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 24 suppl 6 2013 vi7 vi23
16. A. Goldhirsch, C. Wood, and A.S. Coates Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 2011 1736 1747
17. Hornberger J, Chien R. Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice. Poster presented at: St Gallen International Breast Cancer Conference, March 16-14, 2011; St Gallen, Switzerland.
18. R.H. de Boer, C. Baker, D. Speakman, C.Y. Chao, C. Yoshizawa, and G.B. Mann The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer Med J Aust 199 2013 205 208
19. W. Eiermann, M. Rezai, and S. Kümmel et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use Ann Oncol 24 2013 618 624
20. Kanehara, et al. Breast Cancer Guideline of the Japanese Breast Cancer Society, version 2011.
21. S. Lo, P. Mumby, and J. Norton et al. Prospective multicenter study of the impact of the 21-Gene Recurrence Score Assay on medical oncologist and patient adjuvant breast cancer treatment selection J Clin Oncol 28 2010 1671 1676
22. A.M. O'Connor Validation of a decisional conflict scale Med Dec Making 15 1995 25 30
23. O'Connor AM. User Manual - Decisional Conflict Scale. 1993 (updated 2010]). Available at: http://decisionaid.ohri.ca/docs/develop/User-Manuals/UM- Decisional-Conflict.pdf. Accessed April 2, 2009.
24. J. Albanell, A. Gonzales, and M. Ruiz-Borrego et al. Prospective transGEICAM study of Oncotype DX in clinical decision making in women with estrogen receptor-positive, node-negative breast cancer Ann Oncol 23 2012 625 631
25. S.D. Holt, S. Durrani, and D. Pudney et al. Results from a prospective clinical study on the impact of Oncotype DX on adjuvant treatment decision in a cohort of 142 UK patients. Abstracts of the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 6-10, 2011 Cancer Res 71 suppl 3 2011 abstract P5-14-26
26. D.B. Geffen, S. Abu-Ghanem, and N. Sion-Vardy et al. The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy Ann Oncol 22 2011 2381 2386
27. R. Oratz, B. Kim, and C. Chao et al. Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer J Oncol Pract 7 2011 94 99
28. R.H. De Boer, C. Baker, and Speakman et al. Australian Decision Impact Study: the impact of Oncotype DX Recurrence Score (RS) on adjuvant treatment decisions in hormone receptor positive (HR+), node negative and node positive (N+9 early breast cancer (ESBC) in the multidisciplinary clinic. Poster presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 6-10, 2011 Cancer Res 71 suppl 3 2011 abstract P4-09-18